Reata is the closest peer to NEU, similar FDA approved only...

Reata is the closest peer to NEU, similar FDA approved only treated for rare disease.
However, NEU is partnering with Acadia and receiving potentially further US$865m Plus 10% to mid 20% royalties on annual net sales.

Reata's market cap was US$1.187B prior to FDA approval, current market cap stands at US$6.448B;
NEU's market cap was US$0.639B prior to FDA approval, current market cap stands at US$0.98B (with cash A$224m).

Reata's market cap increases by US$5.261B since FDA approval received on 28 February 2023;

NEU's market cap increased by US$0.341B since FDA approval received on 10 March 2023;
NEU's distribution partner, Acadia's market cap increased by US$1.215B since FDA approval;
Combined market cap increases from NEU and Acadia, are US$1.556B, which is far less than Reata's valuation increase of US$5.261B.

Reata, "With that final regulatory hurdle cleared, the SVB Securities team contends Reata’s launch is “worth owning,” with Skyclarys on track to meet or exceed the analysts’ 2023 sales forecast of $45.9 million."

NEU's Daybue, last quarter sales was US$23.2m, and forecast to reach US$45m-55m for current quarter, 2023 sales are likely to well above US$120m.

As yesterday's announcement, NEU will be added into ASX200, that will trigger index funds buys around $70m worth NEU shares over next two weeks, imo.

It's interesting to see what those large funds are going to re-act this massive valuation gap between NEU and Reata.

All imo and GLTA.